Santaris Pharma A/s

Enzon Pharmaceuticals, Inc.

Jens Bo Rode Hansen

Henrik Frydenlund Hansen

Charlotte Albaek Thrue

Majken Westergaard

Ellen Marie Straarup

Margit Wissenbach

Kamille Dumong Petersen

Christoph Rosenbohm

Maj Hedtjärn

Henrik Orum

Niels Fisker Nielsen

The invention provides LNA gapmer oligomers of between 10-20 nucleobases in length, which have a total of 1-3 phosphodiester internucleoside linkages. Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells.

Short oligomer antagonist compounds for the modulation of target mRNA

Short oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with Apo-B100 expression are provided. The oligonucleotides comprise deoxyribonucleosides and locked nucleic acids.

RNA antagonist compounds for the inhibition of Apo-B100 expression

Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Oligomeric compounds for the modulation of survivin expression

Growing community of inventors

Hellerup, Denmark

Jens Bo Rode Hansen